This is a summary of the European public assessment report (EPAR) for Quinsair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Quinsair. For practical information about using Quinsair, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
ATC Code
J01MA12
ATC Item
levofloxacin
Pharmacotherapeutic Group
Antibacterials for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| levofloxacin | N/A | 左氧氟沙星 |
EMA Name
Quinsair
Medicine Name
Quinsair
Aliases
N/A